异基因造血干细胞移植后的肿瘤免疫靶点。
Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation.
作者信息
Ofran Yishay, Ritz Jerome
机构信息
Cancer Vaccine Center, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
出版信息
Clin Cancer Res. 2008 Aug 15;14(16):4997-9. doi: 10.1158/1078-0432.CCR-08-0857.
Abstract
The effectiveness of allogeneic hematopoietic stem cell transplantation for hematologic malignancies results from the donor immunity to antigens expressed in leukemia cells in the recipient. Similar immune responses have now been identified in patients with renal cell cancer with tumor regression after allogeneic hematopoietic stem cell transplantation. Further studies to identify relevant antigens and mechanisms of resistance may improve the effectiveness of this approach in patients with solid tumors.
摘要
异基因造血干细胞移植治疗血液系统恶性肿瘤的有效性源于供体对受体白血病细胞中表达的抗原的免疫反应。目前在接受异基因造血干细胞移植后肿瘤消退的肾细胞癌患者中也发现了类似的免疫反应。进一步研究以确定相关抗原和耐药机制可能会提高这种方法对实体瘤患者的有效性。
相似文献
1
Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后的肿瘤免疫靶点。
Clin Cancer Res. 2008 Aug 15;14(16):4997-9. doi: 10.1158/1078-0432.CCR-08-0857.
2
[Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].[美国实体瘤的异基因造血干细胞移植：综述]
Nihon Rinsho. 2003 Sep;61(9):1619-34.
3
Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions.异基因造血细胞移植作为实体瘤的免疫治疗：现状与未来方向。
J Immunother. 2005 Jul-Aug;28(4):281-8. doi: 10.1097/01.cji.0000165354.19171.8f.
4
Immunobiology of allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植的免疫生物学
Annu Rev Immunol. 2007;25:139-70. doi: 10.1146/annurev.immunol.25.022106.141606.
5
[Hematopoietic stem cell transplantation: is it an immunologic therapy?].[造血干细胞移植：它是一种免疫疗法吗？]
Rev Alerg Mex. 2003 Sep-Oct;50(5):192-7.
6
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.非清髓性预处理后异基因造血细胞移植治疗转移性肾细胞癌：毒性、临床反应及对次要组织相容性抗原的免疫反应
Clin Cancer Res. 2004 Dec 1;10(23):7799-811. doi: 10.1158/1078-0432.CCR-04-0072.
7
Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.异基因造血干细胞移植：一种新兴的实体瘤治疗方式。
Nat Clin Pract Oncol. 2008 May;5(5):256-67. doi: 10.1038/ncponc1104. Epub 2008 Apr 8.
8
Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.异基因造血干细胞移植后的移植物抗宿主病可诱导一种CD8 + T细胞介导的移植物抗肿瘤效应，该效应不依赖于对同种异体抗原性肿瘤靶点的识别。
Blood. 2004 Aug 15;104(4):1210-6. doi: 10.1182/blood-2003-10-3387. Epub 2004 Apr 15.
9
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.对晚期血液系统恶性肿瘤患者进行非清髓性预处理的异基因造血细胞移植。
Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880.
10
Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.实体瘤的非清髓性移植：异基因免疫治疗的新前沿。
Expert Rev Anticancer Ther. 2004 Oct;4(5):865-75. doi: 10.1586/14737140.4.5.865.
引用本文的文献
1
Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation.单倍体相合供者与脐带血异基因造血细胞移植后的免疫重建
Life (Basel). 2021 Jan 29;11(2):102. doi: 10.3390/life11020102.
2
Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results.移植后环磷酰胺促进 HLA 单倍体造血细胞移植：机制与结果。
Semin Hematol. 2019 Jul;56(3):183-189. doi: 10.1053/j.seminhematol.2018.09.002. Epub 2018 Sep 20.
3
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.血液系统恶性肿瘤中的抗原发现与治疗靶点
Cancer J. 2017 Mar/Apr;23(2):115-124. doi: 10.1097/PPO.0000000000000257.
4
Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.血管生成细胞因子是移植物抗白血病反应期间的抗体靶点。
Clin Cancer Res. 2015 Mar 1;21(5):1010-8. doi: 10.1158/1078-0432.CCR-14-1956. Epub 2014 Dec 23.
5
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.影响小鼠体内大型已建立肿瘤的 CD8+ T 细胞过继免疫治疗效果的因素。
Clin Cancer Res. 2011 Aug 15;17(16):5343-52. doi: 10.1158/1078-0432.CCR-11-0503. Epub 2011 Jul 7.
6
[The systemic evaluation and clinical significance of immunological function for advanced lung cancer patients].[晚期肺癌患者免疫功能的系统评价及临床意义]
Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):331-6. doi: 10.3779/j.issn.1009-3419.2010.04.12.
7
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.同种异体造血干细胞移植：癌症的个体化干细胞和免疫治疗。
Nat Rev Cancer. 2010 Mar;10(3):213-21. doi: 10.1038/nrc2804. Epub 2010 Feb 19.
8
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.异基因干细胞移植后早期，经辐照的、自体的、分泌GM-CSF的白血病细胞疫苗的生物活性。
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15825-30. doi: 10.1073/pnas.0908358106. Epub 2009 Aug 26.
本文引用的文献
1
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.C19orf48编码一种次要组织相容性抗原，该抗原可被来自肾细胞癌患者的CD8 + 细胞毒性T细胞识别。
Clin Cancer Res. 2008 Aug 15;14(16):5260-9. doi: 10.1158/1078-0432.CCR-08-0028.
2
Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.异基因造血干细胞移植：一种新兴的实体瘤治疗方式。
Nat Clin Pract Oncol. 2008 May;5(5):256-67. doi: 10.1038/ncponc1104. Epub 2008 Apr 8.
3
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.同种异体干细胞移植后人类肾癌的消退与T细胞对一种人内源性逆转录病毒E（HERV-E）抗原的识别有关。
J Clin Invest. 2008 Mar;118(3):1099-109. doi: 10.1172/JCI34409.
4
Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.作为使用同种异体免疫反应进行免疫治疗靶点的次要组织相容性抗原
Cancer Sci. 2007 Aug;98(8):1139-46. doi: 10.1111/j.1349-7006.2007.00521.x. Epub 2007 May 22.
5
Immunosuppressive strategies that are mediated by tumor cells.由肿瘤细胞介导的免疫抑制策略。
Annu Rev Immunol. 2007;25:267-96. doi: 10.1146/annurev.immunol.25.022106.141609.
6
Induction of tumor immunity following allogeneic stem cell transplantation.异基因干细胞移植后肿瘤免疫的诱导。
Adv Immunol. 2006;90:133-73. doi: 10.1016/S0065-2776(06)90004-2.
7
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.针对H-Y次要组织相容性抗原的抗体反应与慢性移植物抗宿主病及疾病缓解相关。
Blood. 2005 Apr 1;105(7):2973-8. doi: 10.1182/blood-2004-09-3660. Epub 2004 Dec 21.
8
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.非清髓性预处理后异基因造血细胞移植治疗转移性肾细胞癌：毒性、临床反应及对次要组织相容性抗原的免疫反应
Clin Cancer Res. 2004 Dec 1;10(23):7799-811. doi: 10.1158/1078-0432.CCR-04-0072.
9
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion.一种因基因缺失导致差异表达而产生的人类次要组织相容性抗原。
J Exp Med. 2003 May 19;197(10):1279-89. doi: 10.1084/jem.20030044. Epub 2003 May 12.
10
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.检测与免疫诱导慢性粒细胞白血病缓解相关的强效体液反应。
J Clin Invest. 2000 Sep;106(5):705-14. doi: 10.1172/JCI10196.
Zotero 插件